Anuh Pharma Ltd
NSE: ANUHPHR BSE: 506260
₹78.25
(2.65%)
Wed, 18 Mar 2026, 08:04 am
Market Cap7.69B
PE Ratio18.75
Dividend1.95
Health Technology
Pharmaceuticals: Major
24.5KAnuh Pharma Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (3x coverage).
- Anuh Pharma's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Anuh Pharma's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Anuh Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Anuh Pharma is profitable, therefore cash runway is not a concern.
- Anuh Pharma is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (456.5%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 15.4x debt.
- Anuh Pharma's cash and other short term assets cover its long term commitments.
- Anuh Pharma earns more interest than it pays, coverage of interest payments is not a concern.
- Anuh Pharma's level of debt (6.3%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (5.5% vs 6.3% today).
- High level of physical assets or inventory.
management
- The tenure for the Anuh Pharma board of directors is about average.
- Ritesh's remuneration is about average for companies of similar size in India.
- The average tenure for the Anuh Pharma management team is over 5 years, this suggests they are a seasoned and experienced team.
- Ritesh's compensation has increased by more than 20% in the past year whilst earnings fell less than 20%.
misc
- Anuh Pharma is not covered by any analysts.
- Anuh Pharma has significant price volatility in the past 3 months.
past
- Anuh Pharma has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- Anuh Pharma's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Anuh Pharma's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
- Anuh Pharma used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Anuh Pharma has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Anuh Pharma's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- 506260 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 506260 outperformed the Market in India which returned -14.5% over the past year.
- BSE:506260 is up 41.7% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:506260 is up 41.7% outperforming the market in India which returned 8% over the past month.
- Anuh Pharma's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Anuh Pharma's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Anuh Pharma is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Anuh Pharma is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- Anuh Pharma is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800